Use of Metformin in Patients with Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Study Description
The purpose of this research study is to find out whether metformin, an FDA-approved medication for
diabetes, can be safely used and tolerated in people with pseudomyxoma peritonei (PMP) caused by
appendiceal mucinous tumors.
This study is being done because current treatments for recurrent or unresectable PMP are limited, and
early laboratory research suggests that PMP tumors may respond to drugs that affect cellular
metabolism, such as metformin.
Metformin is considered investigational for the treatment of PMP.
Eligibility
You can participate in this study if you
- Have a clinical diagnosis of Pseudomyxoma caused by Appendiceal Mucinous Neoplasms
- Are 18 years old or older
You cannot participate in this study if you
- Are currently taking Metformin
- Are pregnant or planning to get pregnant during the study period